Evidence map›Paper›PMID 28049149›Full record

ArticlemBio2017

RelA Mutant Enterococcus faecium with Multiantibiotic Tolerance Arising in an Immunocompromised Host.

Erin S Honsa, Vaughn S Cooper, Mohammed N Mhaissen, Matthew Frank, Jessica Shaker, Amy Iverson, Jeffrey Rubnitz, Randall T Hayden, Richard E Lee, Charles O Rock and 3 more

Open access · goldAbstract read
In one paragraph

Article in mBio, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers.

0numbers the graph read from it
0cells of the map it votes in
55citing papers in PubMed
6.0field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

55 citing papers in PubMed, 93 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. The Prevalence of Antibiotic Tolerance inPathogens (Basel, Switzerland) · 2024
    Article
  11. The Impact ofPathogens (Basel, Switzerland) · 2024
    Review
  12. Article
  13. In-patient evolution of a high-persisterProceedings of the National Academy of Sciences of the United States of America · 2024
    Article
  14. Review
  15. ClinicalmSphere · 2023
    Article
  16. Article
  17. Review
  18. Article
  19. Prevalence of Antibiotic Tolerance and Risk for Reinfection Among Escherichia coli Bloodstream Isolates: A Prospective Cohort Study.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022
    Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Erin S HonsaDepartment of Infectious Diseases, St. Jude Children's Hospital, Memphis, Tennessee, USA.
Vaughn S CooperDepartment of Microbiology and Molecular Genetics, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.ORCID 0000-0001-7726-0765
Mohammed N MhaissenDepartment of Infectious Diseases, St. Jude Children's Hospital, Memphis, Tennessee, USA.
Matthew FrankDepartment of Infectious Diseases, St. Jude Children's Hospital, Memphis, Tennessee, USA.
Jessica ShakerDepartment of Infectious Diseases, St. Jude Children's Hospital, Memphis, Tennessee, USA.
Amy IversonDepartment of Infectious Diseases, St. Jude Children's Hospital, Memphis, Tennessee, USA.
Jeffrey RubnitzDepartment of Oncology, St. Jude Children's Hospital, Memphis, Tennessee, USA.
Randall T HaydenDepartment of Pathology, St. Jude Children's Hospital, Memphis, Tennessee, USA.
Richard E LeeDepartment of Chemical Biology and Therapeutics, St. Jude Children's Hospital, Memphis, Tennessee, USA.
Charles O RockDepartment of Infectious Diseases, St. Jude Children's Hospital, Memphis, Tennessee, USA.
Elaine I TuomanenDepartment of Infectious Diseases, St. Jude Children's Hospital, Memphis, Tennessee, USA.
Joshua WolfDepartment of Infectious Diseases, St. Jude Children's Hospital, Memphis, Tennessee, USA Joshua.wolf@stjude.org jason.rosch@stjude.org.
Jason W RoschDepartment of Infectious Diseases, St. Jude Children's Hospital, Memphis, Tennessee, USA Joshua.wolf@stjude.org jason.rosch@stjude.org.
St. Jude Children's Research Hospital · USUniversity of Pittsburgh · US

Funding

Predicting the emergence of antibiotic resistance through multi-omics approaches and Immune System-surveillanU01AI124302 · NIAID · BOSTON COLLEGE · PI BENTO, JOSE, COOPER, VAUGHN · 2016 to 2020
$10.2M
REGULATION OF LIPID METABOLISM IN E COLIR01GM034496 · NIGMS · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI ROCK, CHARLES O · 1985 to 2022
$9.2M
PROFESSIONAL ONCOLOGY EDUCATION PROGRAMR25CA023944 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI SUZANNE A. GRONEMEYER · 1986 to 2026
$8.3M
PNEUMOCOCCAL CELL WALL IN MENINGITISR01AI027913 · NIAID · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI TUOMANEN, ELAINE I · 1989 to 2015
$5.2M
Developing therapeutics to treat chronic infectionsR01AI110578 · NIAID · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI LEE, RICHARD E., LEWIS, KIM · 2014 to 2018
$3.8M
Development of Aminospectinomycins for BiodefenseR01AI111449 · NIAID · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI LEE, RICHARD E. · 2014 to 2018
$3.5M
Pneumococcal pathogenesis in sickle cell diseaseR01AI110618 · NIAID · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI ROSCH, JASON W. · 2015 to 2019
$2.2M
NCI NIH HHS R25 CA023944NIAID NIH HHS R01 AI027913NIAID NIH HHS R01 AI110578NIAID NIH HHS R01 AI110618NIAID NIH HHS R01 AI111449NIAID NIH HHS U01 AI124302NIGMS NIH HHS R01 GM034496
6 · The paper itself

Abstract

Serious bacterial infections in immunocompromised patients require highly effective antibacterial therapy for cure, and thus, this setting may reveal novel mechanisms by which bacteria circumvent antibiotics in the absence of immune pressure. Here, an infant with leukemia developed vancomycin-resistant Enterococcus faecium (VRE) bacteremia that persisted for 26 days despite appropriate antibiotic therapy. Sequencing of 22 consecutive VRE isolates identified the emergence of a single missense mutation (L152F) in relA, which constitutively activated the stringent response, resulting in elevated baseline levels of the alarmone guanosine tetraphosphate (ppGpp). Although the mutant remained susceptible to both linezolid and daptomycin in clinical MIC testing and during planktonic growth, it demonstrated tolerance to high doses of both antibiotics when growing in a biofilm. This biofilm-specific gain in resistance was reflected in the broad shift in transcript levels caused by the mutation. Only an experimental biofilm-targeting ClpP-activating antibiotic was able to kill the mutant strain in an established biofilm. The relA mutation was associated with a fitness trade-off, forming smaller and less-well-populated biofilms on biological surfaces. We conclude that clinically relevant relA mutations can emerge during prolonged VRE infection, causing baseline activation of the stringent response, subsequent antibiotic tolerance, and delayed eradication in an immunocompromised state. IMPORTANCE: The increasing prevalence of antibiotic-resistant bacterial pathogens is a major challenge currently facing the medical community. Such pathogens are of particular importance in immunocompromised patients as these individuals may favor emergence of novel resistance determinants due to lack of innate immune defenses and intensive antibiotic exposure. During the course of chemotherapy, a patient developed prolonged bacteremia with vancomycin-resistant Enterococcus faecium that failed to clear despite multiple front-line antibiotics. The consecutive bloodstream isolates were sequenced, and a single missense mutation identified in the relA gene, the mediator of the stringent response. Strains harboring the mutation had elevated baseline levels of the alarmone and displayed heightened resistance to the bactericidal activity of multiple antibiotics, particularly in a biofilm. Using a new class of compounds that modulate ClpP activity, the biofilms were successfully eradicated. These data represent the first clinical emergence of mutations in the stringent response in vancomycin-resistant entereococci.

Indexed as

Drug ToleranceImmunocompromised HostAnti-Bacterial AgentsBacteremiaBiofilmsEnterococcus faeciumFemaleGram-Positive Bacterial InfectionsGuanosine TetraphosphateHumansInfantLigasesMicrobial Sensitivity TestsMutant ProteinsMutation, MissenseSequence Analysis, DNAAnti-Bacterial Agentsguanosine 3',5'-polyphosphate synthetasesGuanosine TetraphosphateLigasesMutant Proteins

Identifiers

PMID28049149
PMCPMC5210501
OpenAlexW2564117813

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.